Cost effectiveness of hepatitis B vaccination strategies in Ireland: An economic evaluation (European Journal of Public Health (2008) 18, 3 (277) DOI: 10.1093/eurpub/ckm123);Cost effectiveness of hepatitis B vaccination strategies in Ireland: An economic evaluation

European Journal of Public Health

Volumn 18, Issue 3, 2008, Pages 275-282

  Tilson, Lesley ^a   Thornton, Lelia ^b   O'Flanagan, Darina ^b   Johnson, Howard ^c   Barry, Michael ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^c DR STEEVENS HOSPITAL   (Ireland)

Author keywords

Cost effectiveness; Economic; Hepatitis B; Ireland; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMICS; EXPERT SYSTEM; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS B; HOSPITAL ADMISSION; HUMAN; INFANT; IRELAND; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MEDICAL FEE; PRIORITY JOURNAL; PROBABILITY; VACCINATION;

EID: 44649114651     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckn121     Document Type: Erratum

References (43)

1. World Health Organisation, Department of Immunisation Vaccines and Biologicals. Introduction of hepatitis B into childhood immunisation services. 2001. Available at: http://www.who.int/vaccines-documents/DocsPDF01/www613.pdf. Accessed on 10 July 2006.
2. Van Damme P, Van Herck K, Leuridan E, et al. Introducing universal hepatitis B vaccine in Europe: differences still remain between countries. Eurosurveillance 2004; 8: Available at: http://www.eurosurveillance.org/ew/2004/ 041118.asp#1. Accessed on 10 July 2006.
3. Immunisation Advisory Committee. Royal College of Physicians of Ireland. Immunisation Guidelines for Ireland, 2002.
4. Health Protection Surveillance Centre. Available at: www.hpsc.ie. Accessed on 4 August 2006.
5. Central Statistics Office. Principal statistics. Available at: http://www.cso.ie. Accessed on 4 August 2006.
6. Health Protection Surveillance Centre. Sexually transmitted infections 2005. Annual Summary Report. December 2006. Available at www.hpsc.ie. Accessed on 4 August 2006.
7. Holliday SM, Faulds D. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics 1994;5:141-71.
8. Beutels P. Economic evaluation of hepatitis B immunisation: a global review of recent studies (1994-2000). Health Economics 2001;10:751-74.
9. Beutels P, Edmunds WJ, Antonanzas F, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002;20:1-7.
10. Aggarwal R, Ghoshal U, Naik S. Assessment of cost-effectiveness of universal hepatitis B immunisation in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003;38:215-22.
11. Vimolket T, Poovorawan Y. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness. Southeast Asian J Trop Med Public Health 2005;36:693-9.
12. Healy C, Cafferkey M, Butler K, et al. Antenatal hepatitis B screening - is there a need for a national policy? Ir Med J 2001;94:111-2.
13. Fitzsimons D, Francois G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005;23:4158-66.
14. Treeage Software Inc. Treeage Pro Healthcare 2006. www.treeage.com. Accessed on 4 August 2006.
15. Fendrick A, Lee J, LaBarge C, et al. Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine. Arch Paediatr Adolesc Med 1999;153:126-36.
16. Harris A, Yong K, Kermode M. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness. Aust N Z J Public Health 2001;25:222-9.
17. Curran M, Goa K. DTP-HBV-IPV/HiB vaccine (Infanrix hexa). Drugs 2003;63:673-82.
18. Tichmann I, Preidel H, Grunert D, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005;23:3272-9.
19. CDC. Epidemiology and prevention of vaccine-preventable diseases: The Pink Book, 9th edn. Washington DC Public Health Foundation: CDC, January 2006.
20. Thornton L, Murphy N, O'Flangan D. The epidemiology of hepatitis B in Ireland. The Health Protection Surveillance Centre, February 2006.
21. Hahne S, Ramsay M, Balogun K, et al. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clin Virol 2004;29:211-20.
22. Ramsay M, Gay N, Balogun K, et al. Control of hepatitis B in the United Kingdom. Vaccine 1998;16:S52-5.
23. General Medical Services (Payments) Board. Annual Report, 31 December 2004.
24. Mullany L. Considerations for implementing a new combination vaccine into managed care. Am J Managed Care 2003;9:S23-9.
25. Department of Health and Children. Consolidated Salary Scales effective from 1st December, 2005. Available at: http://www.dohc.ie. Accessed on 12 June 2006.
26. Briggs A, Goeree R, Blackhouse G, et al. Probabilistic analysis of costeffectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290-308.
27. Levaux H, Schonfeld W, Pellissier J, et al. Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents. Paediatrics 2001;108:317-25.
28. Jacobs J, Saab S, Meyerhoff M. The cost effectiveness of hepatitis immunisation for US college students. J Am Coll Health 2003;51:227-36.
29. Fitzsimons D, Francois G, Emiroglu N, et al. Combined hepatitis B vaccines. Vaccine 2003;21:1310-6.
30. Bloom B, Hillman A, Fendrick A, et al. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Annals Int Med 1993;118:298-306.
31. Mangtani P, Hall A, Normand C. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemiol Community Health 1995;49:238-44.
32. Margolis H, Coleman P, Brown R, et al. Prevention of hepatitis B virus transmission by immunisation: an economic analysis of current recommendations. JAMA 1995;274:1201-8.
33. National Institute for Health and Clincal Excellence (NICE). Guide to the Methods of Technology Appraisal, April 2004. Available at www.nice.org.uk. Accessed on 12 June 2006.
34. Van Damme P, Tormans G, Beutels P, et al. Hepatitis B prevention in Europe: a preliminary economic evaluation. Vaccine 1995;13:S54-7.
35. Fenn P, Gray A, McGuire A. An economic evaluation of universal vaccination against hepatitis B virus. J Infect 1996;32:197-204.
36. Wiebe T, Fergusson P, Horne D, et al. Hepatitis B immunisation in a low-incidence province of Canada: comparing alternative strategies. Med Decis Making 1997;17:472-82.
37. Krahn M, Guasparini R, Sherman M, et al. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health 1998;88:1638-44.
38. Edmunds W. Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies. Commun Dis Public Health 1998;1:221-8.
39. Williams D, Nokes D, Anderson R. Targeted hepatitis B vaccination - a cost effective immunisation strategy for the UK? J Epidemiol Community Health 1996;50:667-73.
40. Wallace L, Young D, Brown A, et al. Costs of running a universal adolescent adolescent hepatitis B vaccination programme. Vaccine 2005;23:5624-31.
41. National Centre for Pharmacoeconomics. Pharmacoeconomic Evaluation. Available at http://www.ncpe.ie/category.php?cid=33. Accessed October 2006.
42. Walshe V, Nash A, Barry M. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Ir Med J 2006;100:144-5.
43. Tilson L, Usher C, Butler K, et al. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland. (in press).